Get the Stockscreener App
27.73
1.10%
0.3005
After Hours:
27.50
-0.23
-0.83%
Agios Pharmaceuticals Inc stock is traded at $27.73, with a volume of 847.65K.
It is up +1.10% in the last 24 hours and down -31.55% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$27.43
Open:
$27.56
24h Volume:
847.65K
Relative Volume:
0.70
Market Cap:
$1.62B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.441
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-5.03%
1M Performance:
-31.55%
6M Performance:
-17.42%
1Y Performance:
-52.98%
1-Day Range:
$27.05
$27.95
1-Week Range:
$26.81
$28.55
52-Week Range:
$22.24
$62.45
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.73 | 1.60B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Intech Investment Management LLC Sells 12,496 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Geode Capital Management LLC Boosts Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does Agios Pharmaceuticals Inc. (8AP) stock trade below intrinsic valueTreasury Yields & Stock Portfolio Risk Management - moha.gov.vn
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO St - GuruFocus
Is Agios Pharmaceuticals Inc. stock a safe haven assetProfit Target & Long Hold Capital Preservation Plans - BỘ NỘI VỤ
(AGIO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Agios falls after mixed data from late-stage trial for sickle cell therapy - MSN
Agios Beats Revenue Forecasts And Eyes PYRUKYND’s Future - Finimize
Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated at Truist Financial - MarketBeat
Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data - Sahm
Truist Securities initiates coverage on Agios Pharma stock with Buy rating - Investing.com Canada
Truist Securities Initiates Coverage on Agios Pharmaceuticals (A - GuruFocus
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
Can PYRUKYND's Thalassemia Review Spark A Turnaround For Agios Shares? - RTTNews
What drives Agios Pharmaceuticals Inc stock priceStock Buyback Updates & Access Powerful Market Insights - earlytimes.in
9 Oversold Biotech Stocks to Invest In - Insider Monkey
The week in pharma: action, reaction and insight – week to November 21 - The Pharma Letter
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutr - GuruFocus
HC Wainwright Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $48.00 - MarketBeat
Health Stocks Reveal A Mixed Bag Of Gains And Losses - Finimize
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):